Sugi Predict

Sugi Predict / Compounds / SCHEMBL200969

SCHEMBL200969

SCHEMBL200969

O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NO)c1ccccc1Br

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ITGB2 P05107 7/20 0.66
▸ ICAM1 P05362 7/20 0.66
▸ ITGAL P20701 7/20 0.66
▸ ECE1 P42892 5/20 0.57
▸ HDAC8 Q9BY41 3/20 0.57
▸ HDAC3 O15379 2/20 0.57
▸ HDAC4 P56524 2/20 0.57
▸ HDAC1 Q13547 2/20 0.57
▸ HDAC7 Q8WUI4 2/20 0.57
▸ HDAC2 Q92769 2/20 0.57
▸ HDAC10 Q969S8 2/20 0.57
▸ HDAC11 Q96DB2 2/20 0.57
▸ HDAC6 Q9UBN7 2/20 0.57
▸ HDAC9 Q9UKV0 2/20 0.57
▸ HDAC5 Q9UQL6 2/20 0.57
▸ MMP2 P08253 2/20 0.56
▸ MMP9 P14780 2/20 0.56
▸ MMP8 P22894 1/20 0.56
▸ CTSL P07711 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1358031 0.90 ITGB2 (0.80) ITGB2ICAM1ITGAL
SCHEMBL1358036 0.90 ITGB2 (0.80) ITGB2ICAM1ITGAL
SCHEMBL16834384 0.78 ITGB2 (0.74) ITGB2ICAM1ITGAL
SCHEMBL30081478 0.78 ITGB2 (0.74) ITGB2ICAM1ITGAL
SCHEMBL9025972 0.76 CTSL (0.76) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL11868630 0.76 ITGB2 (0.80) ITGB2ICAM1ITGAL
SCHEMBL12063160 0.76 ITGB2 (0.71) ITGB2ICAM1ITGAL
SCHEMBL11869919 0.76 ITGB2 (0.80) ITGB2ICAM1ITGAL
SCHEMBL11869604 0.76 ITGB2 (0.80) ITGB2ICAM1ITGAL
SCHEMBL15780958 0.76 ITGB2 (0.79) ITGB2ICAM1ITGAL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 — — US disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 — — US disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 — — US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 — — EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 — — US disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 — — US disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 ITGB2 2890/4885ICAM1 1498/4885ITGAL 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.